<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04301843</url>
  </required_header>
  <id_info>
    <org_study_id>BCC015</org_study_id>
    <nct_id>NCT04301843</nct_id>
  </id_info>
  <brief_title>Eflornithine (DFMO) and Etoposide for Relapsed/Refractory Neuroblastoma</brief_title>
  <official_title>Phase II Trial of Eflornithine (DFMO) and Etoposide for Relapsed/Refractory Neuroblastoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Giselle SaulnierSholler</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>K C Pharmaceuticals Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beat NB Cancer Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Team Parker for Life</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Atrium Health</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Difluoromethylornithine (DFMO) will be used in an open label, multicenter, study in&#xD;
      combination with etoposide for subjects with relapsed/refractory neuroblastoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Difluoromethylornithine (DFMO) will be used in an open label, multicenter, study in&#xD;
      combination with etoposide for subjects with relapsed/refractory neuroblastoma.&#xD;
&#xD;
      In this study subjects will receive six 21-day cycles of Etoposide and DFMO followed by an&#xD;
      additional 630 days of DFMO alone.&#xD;
&#xD;
      Subjects will be evaluated in 3 arms:&#xD;
&#xD;
      • Arm 1: Subjects who show no active disease after receiving any additional therapy for&#xD;
      neuroblastoma that was refractory to standard induction/consolidation therapy.&#xD;
&#xD;
      Refractory: Subjects with progressive disease on upfront therapy OR did not have at least PR&#xD;
      on induction OR required additional second line therapy to achieve remission who are now in&#xD;
      first remission.&#xD;
&#xD;
        -  Arm 2: Subjects who have previously relapsed and currently show no active disease (in&#xD;
           CR2 or greater).&#xD;
&#xD;
        -  Arm 3: Subjects who are relapsed or refractory with active disease.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 25, 2020</start_date>
  <completion_date type="Anticipated">October 1, 2030</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2025</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>Yes</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with event free survival (EFS) during study</measure>
    <time_frame>2 years plus 5 years follow up</time_frame>
    <description>To evaluate the efficacy of difluoromethylornithine (DFMO) in combination with etoposide in patients with relapsed/refractory neuroblastoma, based upon:&#xD;
o Event free survival (EFS) from time of enrollment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Length of time that participants experience Overall Survival (OS)</measure>
    <time_frame>7 years</time_frame>
    <description>To evaluate the efficacy of difluoromethylornithine (DFMO) in combination with etoposide in patients with relapsed/refractory neuroblastoma, based upon:&#xD;
o Overall Survival (OS) from time of enrollment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determine the Overall Response Rate (ORR) of Participants using INSS Response Evaluation Criteria.</measure>
    <time_frame>2 years</time_frame>
    <description>To evaluate the efficacy of difluoromethylornithine (DFMO) in combination with etoposide in patients with relapsed/refractory neuroblastoma, based upon:&#xD;
o Response Rate for patients with active disease (Arm 3) using International Neuroblastoma Staging System (INSS) Response Evaluation Criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Adverse Events as a Measure of Safety and Tolerability</measure>
    <time_frame>2 years plus 30 days</time_frame>
    <description>To monitor the safety and tolerability profile of difluoromethylornithine (DFMO) in combination with etoposide in pediatric and young adult patients with relapsed/refractory neuroblastoma.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">131</enrollment>
  <condition>Neuroblastoma</condition>
  <arm_group>
    <arm_group_label>Eflornithine (DFMO)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In this study subjects will receive six 21-day cycles of Etoposide and DFMO followed by an additional 630 days of DFMO alone.&#xD;
Etoposide will be given at 50 mg/m2/dose PO daily for the first 14 days of each 21 days until 6 cycles of etoposide are completed.&#xD;
DFMO (difluoromethylornithine) will be given at a dose of 1000 mg/m2 BID on each day of study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Eflornithine</intervention_name>
    <description>DFMO (difluoromethylornithine) will be given at a dose of 1000 mg/m2 BID on each day of study.</description>
    <arm_group_label>Eflornithine (DFMO)</arm_group_label>
    <other_name>DFMO</other_name>
    <other_name>difluoromethylornithine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  All patients must have a pathologically confirmed diagnosis of neuroblastoma, ≤ 30.99&#xD;
             years of age with history of relapsed/refractory neuroblastoma.&#xD;
&#xD;
          -  All patients must have completed upfront therapy with at least 4 cycles of aggressive&#xD;
             multi-drug chemotherapy.&#xD;
&#xD;
          -  Specific Criteria by Arm:&#xD;
&#xD;
        Arms 1 and 2:&#xD;
&#xD;
        Subjects with no active disease:&#xD;
&#xD;
        i. No evidence of residual disease by CT/MRI and MIBG scan (or PET for patients who have a&#xD;
        history of MIBG non-avid disease).&#xD;
&#xD;
        o Note: Patients with residual masses detected by CT/MRI may be considered in CR if their&#xD;
        MIBG is negative or if MIBG positive and evaluated by PET and found to have negative PET&#xD;
        scans; biopsy confirmation may be considered if there is still reasonable concern for&#xD;
        persistent disease but is not required.&#xD;
&#xD;
        ii. No evidence of disease metastatic to bone marrow.&#xD;
&#xD;
        Arm 3:&#xD;
&#xD;
        Measurable or evaluable disease, including at least one of the following:&#xD;
&#xD;
        Measurable tumor by CT or MRI; or a positive MIBG and PET; or positive bone marrow&#xD;
        biopsy/aspirate in at least one site.&#xD;
&#xD;
          -  Timing from prior therapy: Enrollment (first dose of DFMO) no later than 60 days from&#xD;
             last dose of the most recent therapy.&#xD;
&#xD;
          -  Subjects must have fully recovered from the acute toxic effects of all prior anti-&#xD;
             cancer chemotherapy and be within the following timelines:&#xD;
&#xD;
               1. Myelosuppressive chemotherapy: Must not have received within 2 weeks of&#xD;
                  enrollment onto this study (6 weeks if prior nitrosourea).&#xD;
&#xD;
               2. Hematopoietic growth factors: At least 5 days since the completion of therapy&#xD;
                  with a growth factor.&#xD;
&#xD;
               3. Biologic (anti-neoplastic agent): At least 7 days since the completion of therapy&#xD;
                  with a biologic agent. For agents that have known adverse events occurring beyond&#xD;
                  7 days after administration, this period must be extended beyond the time during&#xD;
                  which adverse events are known to occur. The duration of this interval must be&#xD;
                  discussed with the Study Chair.&#xD;
&#xD;
               4. Immunotherapy: At least 6 weeks since the completion of any type of&#xD;
                  immunotherapy, e.g. tumor vaccines, CAR-T cells.&#xD;
&#xD;
               5. Anti-GD2 Monoclonal antibodies: At least 2 weeks must have elapsed since prior&#xD;
                  treatment with a monoclonal antibody.&#xD;
&#xD;
               6. XRT: At least 14 days since the last treatment except for radiation delivered&#xD;
                  with palliative intent to a non-target site.&#xD;
&#xD;
               7. Stem Cell Transplant:&#xD;
&#xD;
                    1. Allogeneic: No evidence of active graft vs. host disease&#xD;
&#xD;
                    2. Allo/Auto: ≥ 2 months must have elapsed since transplant.&#xD;
&#xD;
               8. MIBG Therapy: At least 8 weeks since treatment with MIBG therapy&#xD;
&#xD;
          -  Subjects must have a Lansky or Karnofsky Performance Scale score of 60% or higher.&#xD;
&#xD;
          -  Life expectancy &gt; 2 months&#xD;
&#xD;
          -  All clinical and laboratory studies for organ functions to determine eligibility must&#xD;
             be performed within 7 days prior to first dose of study drug unless otherwise&#xD;
             indicated below.&#xD;
&#xD;
          -  Subjects must have adequate organ functions at the time of registration:&#xD;
&#xD;
               -  Hematological: Total absolute neutrophil count ANC ≥750/μL&#xD;
&#xD;
               -  Liver: Subjects must have adequate liver function as defined by AST and ALT &lt;5x&#xD;
                  upper limit of normal (Normal=45), Bilirubin &lt;1.5x upper limit normal&#xD;
                  (Normal=1.0). Normal PT, PTT, fibrinogen.&#xD;
&#xD;
               -  Renal: Adequate renal function defined as (perform one of the following):&#xD;
                  Creatinine clearance or radioisotope GFR 70 mL/min/1.73 m2 or greater or a serum&#xD;
                  creatinine based on age/gender&#xD;
&#xD;
          -  Females of childbearing potential must have a negative pregnancy test. Patients of&#xD;
             childbearing potential must agree to use an effective birth control method. Female&#xD;
             patients who are lactating must agree to stop breast-feeding.&#xD;
&#xD;
          -  Written informed consent in accordance with institutional and FDA guidelines must be&#xD;
             obtained from all subjects (or patients' legal representative).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  BSA of &lt;0.25 m2.&#xD;
&#xD;
          -  Subjects that received DFMO at a dose higher than 1000mg/m2 BID prior to this study&#xD;
             are not eligible.&#xD;
&#xD;
          -  Subjects that received a dose of DFMO in combination with etoposide are not eligible.&#xD;
&#xD;
          -  Investigational Drugs: Subjects who are currently receiving another investigational&#xD;
             drug are excluded from participation.&#xD;
&#xD;
          -  Anti-cancer Agents: Subjects who are currently receiving other anticancer agents are&#xD;
             not eligible. Subjects must have fully recovered from hematological and bone marrow&#xD;
             suppression effects of prior chemotherapy.&#xD;
&#xD;
          -  Infection: Subjects who have an uncontrolled infection are not eligible until the&#xD;
             infection is judged to be well controlled in the opinion of the investigator.&#xD;
&#xD;
          -  Subjects who, in the opinion of the investigator, may not be able to comply with the&#xD;
             safety monitoring requirements of the study, or in whom compliance is likely to be&#xD;
             suboptimal, should be excluded.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>31 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Giselle Sholler, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Beat Childhood Cancer</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Genevieve Bergendahl, MSN</last_name>
    <phone>704.355.1220</phone>
    <email>genevieve.bergendahl@atriumhealth.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Shari McKee</last_name>
    <phone>704.355.1220</phone>
    <email>sharon.mckee@atriumhealth.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Arkansas Children's Hospital</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Susan Hall</last_name>
      <phone>501-364-2760</phone>
      <email>HallSF@archildrens.org</email>
    </contact>
    <investigator>
      <last_name>Kathleen Neville, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UCSF Benioff Children's Hospital Oakland-</name>
      <address>
        <city>Oakland</city>
        <state>California</state>
        <zip>94609</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Effie Bourgin</last_name>
      <email>EBourgin@mail.cho.org</email>
    </contact>
    <investigator>
      <last_name>Anurag Agrawal, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rady Children's Hospital</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mehrzad Milburn</last_name>
      <phone>858-966-8155</phone>
    </contact>
    <investigator>
      <last_name>William Roberts, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Connecticut Children's Hospital</name>
      <address>
        <city>Hartford</city>
        <state>Connecticut</state>
        <zip>06106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Amy Newton</last_name>
      <phone>860-545-9337</phone>
      <email>ANewton@connecticutchildrens.org</email>
    </contact>
    <investigator>
      <last_name>Michael Isakoff, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Arnold Palmer Hospital for Children</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jessica El-Shami</last_name>
      <phone>321-841-8588</phone>
      <email>Jessica.El-Shami@orlandohealth.com</email>
    </contact>
    <investigator>
      <last_name>Don Eslin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kapiolani Medical Center for Women and Children</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96813</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Andrea Siu, MPH</last_name>
      <phone>808-535-7169</phone>
      <email>andrea.siu@kapiolani.org</email>
    </contact>
    <investigator>
      <last_name>Randal Wada, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital and Clinics on Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Courtney Haller</last_name>
      <phone>612-813-5913</phone>
      <email>courtney.haller@childrensmn.org</email>
    </contact>
    <investigator>
      <last_name>Jawhar Rawwas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cardinal Glennon Children's Medical Center</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Katherine Maxwell, RN</last_name>
      <phone>314-268-4000</phone>
    </contact>
    <investigator>
      <last_name>William Ferguson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Levine Children's Hospital</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Abigail Moore</last_name>
      <phone>980-442-2356</phone>
      <email>Abigail.Moore@atriumhealth.org</email>
    </contact>
    <contact_backup>
      <last_name>Lauren Smith</last_name>
      <email>Lauren.Smith7@atriumhealth.org</email>
    </contact_backup>
    <investigator>
      <last_name>Javier Oesterheld, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Penn State Milton S. Hershey Medical Center and Children's Hospital</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Suzanne Treadway</last_name>
      <email>streadway@hmc.psu.edu</email>
    </contact>
    <investigator>
      <last_name>Valerie Brown, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sydney Bargeloh</last_name>
      <phone>843-792-2957</phone>
      <email>BROWNSY@musc.edu</email>
    </contact>
    <investigator>
      <last_name>Jaqueline Kraveka, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dell Children's Blood and Cancer Center</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78723</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Rhea Robinson, RN</last_name>
      <phone>512-628-1902</phone>
      <email>TXAUS-DL-SFCHemonc.research@ascension.org</email>
    </contact>
    <investigator>
      <last_name>Virginia Harrod, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.beatcc.org</url>
    <description>Beat Childhood Cancer Consortium website</description>
  </link>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>March 6, 2020</study_first_submitted>
  <study_first_submitted_qc>March 6, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 10, 2020</study_first_posted>
  <last_update_submitted>October 4, 2021</last_update_submitted>
  <last_update_submitted_qc>October 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Atrium Health</investigator_affiliation>
    <investigator_full_name>Giselle SaulnierSholler</investigator_full_name>
    <investigator_title>Chair, Beat Childhood Cancer</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuroblastoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Eflornithine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

